抑郁症患者的血清S100B蛋白的研究进展

S100B蛋白是诊断抑郁症的血清标志物之一,是目前研究抑郁症诊断的热点之一。S100B作为一种新型蛋白,它的发现为抑郁症的诊断提供了一个可能的标志物。本文就近年来的实验研究总结S100B蛋白与抑郁症的关系。     

脑梗死后抑郁症患者血清 S100B 蛋白浓度的变化及意义

目的：探讨脑梗死后抑郁症患者血清S100B蛋白浓度的变化及意义。方法选取2010-01-2012-01在我院接受治疗的300例脑梗死患者,采用汉密尔顿抑郁量表HAMD进行抑郁症筛查,脑梗死后抑郁症患者125例为实验组（A组）,余下单纯脑梗死患者175例中随机选取125例为对照组（B组）。观察2组治疗前后血清S100B蛋白浓度变化和病情改变情况。结果A组患者治疗前HAMD评分（21.80±6.01）分,治疗后为（14.45±3.82）分,差异有统计学意义（P＜0.05）;治疗前血清S100B蛋白浓度（0.32±0.083）μg/L,治疗后为（0.21±0.056）μg/L,差异有统计学意义（P＜0.05）。治疗前后A组血清S100B蛋白浓度均高于同期B组,差异有统计学意义（P＜0.05）;B组治疗前后血清S100B蛋白浓度变化不明显（P＞0.05）。结论脑梗死后抑郁症患者抗抑郁治疗后血清S100B蛋白浓度显著降低,抑郁症病情改善,血清S100B蛋白浓度可作为脑梗死病情、预后、抑郁症发作和抗抑郁治疗效果的预测指标。     

脑梗死后抑郁症患者血清S100B蛋白浓度的变化及意义

目的探讨脑梗死后抑郁症患者血清S100B蛋白浓度的变化及意义。方法选取2010-01—2012-01在我院接受治疗的300例脑梗死患者,采用汉密尔顿抑郁量表HAMD进行抑郁症筛查,脑梗死后抑郁症患者125例为实验组（A组）,余下单纯脑梗死患者175例中随机选取125例为对照组（B组）。观察2组治疗前后血清S100B蛋白浓度变化和病情改变情况。结果 A组患者治疗前HAMD评分（21.80±6.01）分,治疗后为（14.45±3.82）分,差异有统计学意义（P〈0.05）;治疗前血清S100B蛋白浓度（0.32±0.083）μg/L,治疗后为（0.21±0.056）μg/L,差异有统计学意义（P〈0.05）。治疗前后A组血清S100B蛋白浓度均高于同期B组,差异有统计学意义（P〈0.05）;B组治疗前后血清S100B蛋白浓度变化不明显（P〉0.05）。结论脑梗死后抑郁症患者抗抑郁治疗后血清S100B蛋白浓度显著降低,抑郁症病情改善,血清S100B蛋白浓度可作为脑梗死病情、预后、抑郁症发作和抗抑郁治疗效果的预测指标。     

血清S100B蛋白水平与首发抑郁症关系的研究

目的 探讨首发抑郁症患者的血清S100B蛋白水平与抑郁症及其认知功能的关系.方法 纳入符合美国精神障碍诊断与统计手册第四版(DSM-Ⅳ)抑郁症诊断标准的首发抑郁症患者30例和正常对照30名,检测血清S100B蛋白水平,同时应用17项版本汉密尔顿抑郁量表(HAMD)和威斯康星卡片分类测验(WCST)评定患者的病情和认知功能.并进行两组间比较.结果 患者组血清S100B蛋白水平明显高于对照组[(0.109±0.032)μg/L与(0.033±0.014)μg/L,P<0.01].患者组WCST的完成分类数得分低于对照组,差异有统计学意义(P<0.01),而错误应答数、完成第一个分类所需应答数、持续性错误数、持续性应答和持续性错误百分数均高于对照组,差异均有统计学意义(P<0.01).患者组血清S100B蛋白水平与HAMD的总分、阻滞因子分及睡眠障碍因子分呈正相关(r为0.46、0.41和0.37,P均小于0.05),与WCST中的持续性错误数、持续性应答及持续性错误百分数呈正相关(r为0.39、0.37和0.37,P均小于0.05).结论 首发抑郁症患者血清S100B蛋白水平升高,其升高程度与抑郁症的严重程度和认知损害程度正相关.     

急性缺血性脑卒中患者治疗前后血清S100B蛋白变化及其意义

目的探讨急性缺血性脑卒中患者治疗前后血清S100B蛋白的变化及其临床意义。方法采用ELISA法检测86例急性缺血性脑卒中患者治疗前后及46例正常人的血清S100B蛋白水平。结果急性缺血性脑卒中患者治疗前的血清S100B蛋白水平显著高于对照组（P〈0．001），差异有统计学意义；急性缺血性脑卒中患者治疗后血清S100B蛋白水平显著下降（P〈0．001），差异有统计学意义。结论急性缺血性脑卒中发生时，患者血清S100B蛋白增高；治疗后检测急性缺血性脑卒中患者血清S100B蛋白水平有助于早期诊断、指导治疗及判断预后。     

抑郁症患者血清S100B浓度的变化及其影响因素的相关性分析

目的 观察抑郁症患者血清S100B浓度的变化,并分析其与抑郁症患者的首发年龄、发作次数、临床症状严重程度之间的相关性.方法 研究对象为抑郁症患者79例,以及年龄和性别相匹配的健康体检者79例.利用酶联免疫吸附法检测血清S100B的浓度,采血同时利用17项汉密尔顿抑郁量表(HAMD-17)评定临床症状的严重程度.结果 抑郁症患者血清S100B浓度(0.15±0.03)μg/L高于正常组(0.11±0.03)μg/L,差异具有统计学意义(P＜0.01);抑郁症患者的发作次数、症状的严重程度与血清S100B有相关性.结论 血清S100B可能作为抑郁症诊断的生化指标,并且在抑郁症疾病的发展中具有一定的作用.     

S100B蛋白生物学研究与临床应用进展

S100蛋白是一种分子量较小（10～12ku）的EF-手型钙结合蛋白，通过对钙离子的调节及与靶蛋白的相互作用，在体内发挥多种生物学作用．在细胞增殖、分化，肌肉收缩、基因表达、分泌及细胞凋亡中发挥重要作用。1965年Moore等首先在牛脑组织中发现S100蛋白，因其在中性饱和硫酸铵中100％溶解而得名。现已发现S100蛋白家族成员20个，S100B蛋白为其中一员，     

急性缺血性脑卒中患者治疗前后血清S100B蛋白变化及其意义

目的探讨急性缺血性脑卒中患者治疗前后血清S100B蛋白的变化及其临床意义。方法采用ELISA法检测86例急性缺血性脑卒中患者治疗前后及46例正常人的血清S100B蛋白水平。结果急性缺血性脑卒中患者治疗前的血清S100B蛋白水平显著高于对照组(P<0.001),差异有统计学意义;急性缺血性脑卒中患者治疗后血清S100B蛋白水平显著下降(P<0.001),差异有统计学意义。结论急性缺血性脑卒中发生时,患者血清S100B蛋白增高;治疗后检测急性缺血性脑卒中患者血清S100B蛋白水平有助于早期诊断、指导治疗及判断预后。     

急性颅脑损伤后血清S100B蛋白含量变化

目的研究血清中S100B蛋白含量变化与颅脑损伤患者病情的关系。方法应用电化学发光免疫法测定36例急性颅脑损伤患者伤后不同时间血清S100B蛋白含量变化，结合GCS评分进行分析，并与对照组（20例无神经系统疾病史者）进行比较。结果颅脑损伤后24、48、72h和1周患者血清S100B蛋白水平均较对照组明显升高（P〈0．01）；颅脑损伤越严重，S100B蛋白水平升高越明显．伤后早期（48h内）重型（GCS评分≤7分）者血清S100B蛋白水平明显高于中、轻型（GCS评分≥8分）者（P〈0．01）。结论急性颅脑损伤后血清S100B含量明显升高，并与患者病情密切相关。     

脑梗死患者血清S100B蛋白的动态变化及其临床意义

目的 探讨脑梗死患者血清S100B蛋白的动态变化及其临床意义。方法 用双抗体夹心（ELISA）法测定41例脑梗死患者和99例对照者血清S100B蛋白水平，同时观察其中4例患者血清S100B蛋白动态变化。结果 脑梗死患者血清S100B蛋白水平显著高于对照组（P＜0．001），发病后24小时开始升高，第2－3天达到高峰。尤其梗死面积大的中、重型患者明显升高。结论 血清S100B蛋白质升高是脑梗死早期脑损伤的重要标志之一。     

RAGE基因多态性与高血压左室肥厚、血清esRAGE水平的相关性研究

目的探讨晚期糖基化终末产物受体(RAGE)基因Gly82Ser多态性与EH-LVH患者及其血清内源性分泌型RAGE(esRAGE)水平的相关性。方法应用聚合酶链反应-限制性片段多态性(PCR-RLFP)的方法,检测94例EH患者(其中38例伴LVH)及50例对照组RAGE基因Gly82Ser多态性,同时采用ELISA法测定血清esRAGE水平。结果与正常对照组相比,EH组基因型频率和等位基因频率差异无统计学意义(P>0.05);EH-LVH组RAGE基因Gly82Ser位点的GS基因型频率和82Ser等位基因频率明显增高,差异有统计学意义(P<0.05);EH-LVH和EH组Gly82Ser SS基因型血清es-RAGE水平与对照组相比差异显著(P<0.05)。结论 RAGE基因Gly82Ser多态性与EH的发生发展无关;EH-LVH患者RAGE基因Gly82Ser GS基因型和82Ser等位基因增多,提示82Ser等位基因可能是EH-LVH发病的易感基因;RAGE基因Gly82Ser多态性与血清esRAGE水平显著相关。     

The effects of gender and numbers of depressive episodes on serum S100B levels in patients with major depression

S100B protein is a calcium-binding protein mostly derived from glial cells, which exerts trophic or toxic effects on neural cell depending on its concentration. It has been reported that S100B played an important role as a potential marker in psychiatric disorders. Thus, we will explore the clinical implication of S100B in major depression, especially the effect of gender and numbers of depressive episodes on S100B. The levels of serum S100B were measured with enzyme-linked immunosorbent assay (ELISA) in 54 patients with major depression and 35 age-matched healthy controls. The S100B levels in major depressed patients were significantly higher than those in controls. The serum S100B levels in female patients were significantly higher than those in male patients. Patients with recurrent depressive episodes had significantly higher S100B levels than those in first-episode depression. Serum S100B levels were significantly positive related with the numbers of depressive episode, family history and cognitive disturbance scores. These findings confirmed an increase in serum S100B levels in major depressive patients and presence of a sexual dimorphism. Moreover, numbers of depressive episodes in depression seemed to have an additional increasing effect on S100B levels.     

SSRI类药物对抑郁症患者esRAGE水平及血糖的影响

目的 探讨SSRI类药物对抑郁症患者血清内源性分泌型糖基化终产物受体(esRAGE)水平及血糖的影响.方法 采用SSRI类药物对28例抑郁症患者进行为期6周的治疗,分别在治疗前和治疗6周后,用酶联免疫法测定抑郁症患者血清中esRAGE浓度和血糖水平,并与34例正常对照者比较.结果 (1)抑郁症组治疗后esRAGE浓度[(0.56±0.17)ng/ml]高于治疗前[(0.49±0.21)ng/ml],但均低于正常对照组[(0.66±0.10)ng/ml],组间比较差异有显著统计学意义(P＜0.001).(2)抑郁症组治疗后空腹血糖[(4.91±0.50)mmol/L]低于治疗前[(5.38±0.39)mmol/L],差异有显著统计学意义(P=0.000),但与正常对照组空腹血糖[(5.08±0.41)mmol/L]比较差异无统计学意义(P=0.172).(3)Pearson相关分析显示,esRAGE与空腹血糖成中等程度负相关(P＜0.05).结论 SSRI类药物能升高抑郁症患者的esRAGE水平,同时降低血糖水平.     

S100B and NSE serum levels in patients with Parkinson's disease

We evaluated S100B protein and neuron-specific enolase (NSE) serum levels in Parkinson's disease (PD) patients and their correlation with the severity of disease. The levels of S100B (P=0.16) and NSE (P=0.39) between PD and controls were similar. However, S100B levels correlated positively with the Hoehn and Yahr scale (r=0.368; P=0.02) and negatively with the Activities of Daily Living (ADL) scale (r=-0.431; P=0.006). Therefore, S100B and NSE may not have a diagnostic role in PD, but S100B may have a potential role as a marker of disease progression. The study of S100B may also contribute to elucidate the controversial role of glial cells in PD.     

精神分裂症伴发迟发性运动障碍的血清S100B蛋白浓度研究

目的 比较伴发和未伴发迟发性运动障碍(tardive dyskinesia,TD)的慢性精神分裂症患者血清S100B蛋白的浓度,探索S100B蛋白在TD发生中的作用.方法 采用酶联免疫吸附法检测95例伴发TD(TD组,n ＝ 40)与未伴发TD(非TD组,n ＝ 55)的慢性精神分裂症患者和40名正常对照的血清S100B蛋白浓度,比较3组间的差异;采用阳性和阴性症状量表(positive and negative syndrome scale,PANSS)评定精神病理症状,采用异常不自主运动量表(abnormal involuntary movement scale,AIMS)评定TD严重程度,分析血清S100B蛋白浓度与精神病理症状、TD严重程度的关系.结果 TD组、非TD组和对照组的血清S100B蛋白浓度分别为(0.17 ± 0.04)μg/L、(0.15 ± 0.02)μg/L和(0.10 ± 0.03)μg/L,3组的差异有统计学意义(F ＝ 53.07,P ＜ 0.01),前两者均明显高于对照组(P ＜ 0.01),且TD组高于非TD组(P ＜ 0.01).TD组血清S100B蛋白浓度与AIMS总分正相关(r ＝ 0.52,P ＜ 0.01).结论 TD患者血清S100B蛋白浓度较非TD患者还高,而且与TD严重程度正相关,提示胶质细胞功能异常可能在TD发生、发展过程中可能起一定作用.     

Reduced serum levels of adiponectin in elderly patients with major depression

Recent studies have implicated adiponectin and other adipocytokines in brain function, particularly in processes related to memory and cognition. Blood levels of adiponectin are reduced in patients with primary cognitive disorders, such as Alzheimer's disease and mild cognitive impairment, and in adult patients with major depression. The aim of the present study is to determine serum levels of adiponectin in a sample of elderly patients with major depressive disorder (MDD) as compared to healthy older adults, and to examine the correlations between adiponectin levels and parameters indicative of mood and cognitive state. We recruited fifty-one unmedicated outpatients with late-life depression (LLD) and 47 age-matched controls in this study. The diagnosis of MDD was made according to the DSM-IV criteria, and the severity of depressive episode was determined with the 21-item Hamilton Depression Scale (HDRS). Cognitive state was ascertained with the Cambridge Cognitive Test (CAMCOG) and the Mini-Mental State Examination (MMSE). Serum concentrations of adiponectin were determined using a sandwich ELISA method. Serum levels of adiponectin were significantly reduced in individuals with LLD (F = p < 0.001). Adiponectin level remained significantly reduced in after controlling for BMI index, scores on the CAMCOG, MMSE and HDRS and educational level (p < 0.001). Adiponectin levels showed a negative correlation with HDRS scores (r = ?0.59, p < 0.001) and BMI index (r = ?0.42, p < 0.001); and showed a positive correlation with CAMCOG (r = 0.34, p < 0.01) and MMSE scores (r = 0.20, p = 0.05). The availability of circulating adiponectin is reduced in older adults with major depression, with likely implications on cognitive and mood state. Additional studies are required to determine whether this abnormality pertains to the pathophysiology of geriatric depression per se, or is a consequence of the morbid state.     

Prediction of postdexamethasone cortisol levels by serum sodium levels in patients with major depression

The authors analyzed the dexamethasone suppression test (DST) results of 54 patients with major depressive disorder in relation to their pre-DST levels of cholesterol, sodium, potassium, and blood glucose, which are thought to have adrenocorticotrophic links. Discriminant analysis revealed that sodium alone was a significant predictor of nonsuppression. Validation of the predictive power of sodium could minimize the need for DST administration.     

Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: Association with dyskinetic movements

Several studies show that calcium-binding protein S100B is increased in schizophrenia and may be involved in the pathogenesis of tardive dyskinesia (TD). We therefore compared serum S100B levels in normal controls (n = 60), schizophrenic patients with (n = 32) and without TD (n = 50). Assessments included the abnormal involuntary movement scale (AIMS) and the positive and negative syndrome scale (PANSS). Serum S100B levels were measured by enzyme-linked immunosorbent assay (ELISA). The results indicated that patients with TD had higher serum S100B levels than normals and those without TD. Serum S100B levels were positively correlated with AIMS scores in patients with TD. These data suggest that increased S100B levels may be related to neuro-degeneration, associated with TD pathophysiology.     

Clinical significance of serum S100B levels in neurointensive care

Objective  S100B is viewed as the most promising biomarker for brain damage. It has been proposed that this marker is useful in a Neurointensive Care Unit (NICU) as a monitoring parameter. This study aims to examine the clinical usefulness of daily serum S100B measurements in this setting. Design  Prospective consecutive inclusion of patients. Patients  A total of 79 patients with confirmed or suspected head injury or cerebrovascular insults (CVIs) (based upon patient history, computed tomography (CT) and/or magnetic resonance imaging (MRI) and neurological examination including coma scoring) who required neurointensive care were included in the study. Interventions  Sampling for S100B was performed at admission and daily until patients were discharged from the NICU. S100B measurements were statistically compared to occurrence of secondary complications and outcome according to Glasgow Outcome Scale (GOS), with focus on clinical prediction. Measurements and main results  17 of 79 patients (22%) had secondary neurological complications. Mean S100B levels were found to be an independent parameter associated with these complications (P = 0.03). Mean S100B levels were higher in patients with complications compared to those without on both the complication day (P = 0.033) and the day after (P = 0.015), but not the day prior to the complication (P = 0.62). S100B did not predict secondary neurological complication. Neither mean (P = 0.182) nor peak (P = 0.370) S100B levels were associated with or predicted outcome according to dichotomised GOS. Conclusion  Daily S100B measurements are associated with secondary complications but not to outcome. However, daily S100B levels do not predict secondary complications, which limit the usefulness of this brain biomarker in this setting. This work was performed at the Neurointensive Care Unit at the department of Neurosurgery, Lund University Hospital, Lund, Sweden.     

The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis

The association of nocturnal serum melatonin levels was investigated in acute multiple sclerosis (MS) patients with major depression (MD). The sample comprised 13 patients with MD and 12 with no psychiatric disorders admitted to our clinic due to acute MS attacks. Psychiatric evaluation was performed with the Structured Clinical Interview for DSM-IV (SCD-I). The level of depressive symptoms was assessed with the Beck Depression Scale (BDS). Blood samples were taken from the patients to determine melatonin level at 03.30 h and 10.00 h before steroid treatment started. Melatonin levels were determined using the ELISA test. Nocturnal serum melatonin levels (21.2+/-17.1 pg/ml) of the patients with MD were significantly lower than those (51.5+/-18.3 pg/ml) of the patients without MD. A significant negative correlation was found between BDS scores and nocturnal serum melatonin levels. These findings suggest that a melatonin deficiency may be among the factors involved in the occurrence of depression in MS patients.